Announced
Completed
Financials
Sources
Tags
Reverse Takeover
Pharmaceuticals
Friendly
biopharmaceutical company
De-SPAC
Merger
Iceland
Majority
Private
Acquisition
Private Equity
Single Bidder
Cross Border
Completed
Synopsis
Alvotech, a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, went public via merger with Oaktree Acquisition II, a special purpose acquisition company sponsored by an affiliate of Oaktree Capital, in a $2.25bn deal. The deal includes a $150m PIPE investment from Suvretta Capital, Athos, CVC Capital Partners, Temasek, Farallon Capital Management, Sculptor Capital Management, Arctica Finance, Arion Bank, and Landsbankinn. "We are delighted with this business combination and the long-term opportunities it will unlock for Alvotech. Through this important milestone, we believe that we are perfectly positioned to rapidly scale our portfolio with a like-minded partner who understands the intricacies of our business and our industry," Robert Wessman, Alvotech Chairman and Founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.